Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

NCT07424547 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

386

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer
Solid Tumor Cancer
Advanced Metastatic Cancer
Prostate
Small Cell Lung Cancer
Ovarian Cancer
Breast Cancer

Interventions

DRUG: SYS6043

Sponsor

Conjupro Biotherapeutics, Inc.